NEWAMSTERDAM Aktie

 

NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 40,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4)....

NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:...

NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 18,000 of NewAmsterdam's ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee's acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4)....

– Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency –...

NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the......

NewAmsterdam Pharma Company N.V. (NAMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 11:00 a.m. ET....

Topper, James N. - Aufsichtsrat - Tag der Transaktion: 2025-09-15...

On September 12, several healthcare and biotech stocks experienced a surge in after-hours trading, marked by sharp price movements across the sector. From thrombectomy devices to AI-powered diagnostics and T-cell therapies, companies including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma posted notable gains after hours. While some moves were tied to strategic ......

Kooij, Louise Frederika - Vorstand - Tag der Transaktion: 2025-09-09...

Topper, James N. - Aufsichtsrat - Tag der Transaktion: 2025-09-08...

Kooij, Louise Frederika - Vorstand - Tag der Transaktion: 2025-09-03...

If approved, obicetrapib, licensed from NewAmsterdam Pharma, would be the first CETP inhibitor to be available, as an adjunct to diet, for patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia and unable to reach low-density......

Kooij, Louise Frederika - Vorstand - Tag der Transaktion: 2025-08-25...

Kastelein, Johannes Jacob Pieter - Vorstand - Tag der Transaktion: 2025-08-22...

Kastelein, Johannes Jacob Pieter - Vorstand - Tag der Transaktion: 2025-08-21...

The investment equips NewAmsterdam Pharma with the commercial capability to produce a fixed dose combination (FDC) of obicetrapib and ezetimibe, thereby addressing potential market demand. Piramal Pharma Solutions The post Piramal Pharma opens oral solid dosage suite in Pennsylvania, US appeared first on Pharmaceutical Business review....

read more...

Piramal Pharma Solutions: Mumbai, Indien (ots/PRNewswire) - - Die Investition in Höhe von mehreren Millionen Dollar verschafft NewAmsterdam Pharma kommerzielle Kapazitäten für die Fixkombination (FDC) von Obicetrapib und Ezetimib, um die potenziell hohe kommerzielle ......

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently......